Corresponding author: Takashi Ono, firstname.lastname@example.org
Received: March 21, 2019
Accepted: July 18, 2019
Advance Publication: September 10, 2019
Published: January 15, 2020
Cite this article as:
Ono T, Iwasaki T, Miyata K. Bilateral Corneal Opacity of Fish-eye Disease. JMA J. 2020;3(1):73-74.
Key words: Fish-eye disease, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, corneal opacity
A 46-year-old woman presented to the hospital with photophobia. She was afebrile and had no systemic complaints. Ophthalmologic slit-lamp examination showed bilateral diffuse corneal opacity that was denser in the peripheral areas (Figure 1A). Although the corneal opacity progressed after 15 years of observation (Figure 1B), her best-corrected visual acuity remained 1.5 bilaterally. Laboratory findings showed that her serum high-density lipoprotein cholesterol (HDL-C) was 2 mg/dL, and her low-density lipoprotein cholesterol was 105 mg/dL. Her complete blood count and renal function were normal. Both her serum lecithin cholesterol acyltransferase (LCAT) activity (less than 70 nmol/mL/h) and apolipoprotein-A1 level (14 mg/dL) were low. Further examination showed that she had the same mutations in LCAT gene homozygously (c. 440 C>T, p.T147I) as reported (1). She was diagnosed with fish-eye disease. Patients with fish-eye disease show markedly low HDL-C with corneal opacities, and they typically tend to develop cardiovascular disease later in life (2).
Written informed consent was obtained from the subject prior to the collection of any data.
Funke H, von Eckardstein A, Pritchard PH, et al. Genetic and phenotypic heterogeneity in familial lecithin: cholesterol acyltransferase (LCAT) deficiency. Six newly identified defective alleles further contribute to the structural heterogeneity in this disease. J Clin Invest. 1993;91(2):677-83.
Schaefer EJ, Anthanont P, Diffenderfer MR, et al. Diagnosis and treatment of high density lipoprotein deficiency. Prog Cardiovasc Dis. 2016;59(2):97-106.